title: Hepatitis C virus infection in dialysis patients.
abstract: Hepatitis C virus (HCV) infection is a global health problem, common worldwide, leading to acute and chronic hepatitis and its consequences of hepatocirrhosis and hepatocellular carcinoma. Patients on hemodialysis belong to the high-risk group of HCV infection. The prevalence of HCV infection in dialysis patients ranges from 4% to more than 70% in some countries. The main reasons for such a high incidence of infections are a high prevalence of HCV infection in the general population, lack of standard infection precautions and effective vaccination, inadequate disinfection procedures of dialysis machines and other medical equipment, as well as spread of infection from patient to patient, especially in dialytic centers with a high percentage of infected patients. The diagnostic procedures useful in the evaluation of HCV infection are detection of anti-HCV antibodies, identification of HCV RNA, counts of virus copies, and identification of its genome. From the 6 major genotypes and multiple subtypes of the HCV, genotypes 1a and 1b are the most common in Europe and Japan, and 1b is responsible for more severe liver disease and aggressive course leading to liver fibrosis. Antiviral therapy of HCV+ dialysis patients with interferon-alpha (INF-alpha) gives slightly better results than in the general population, but is poorly tolerated and associated with side effects. Although ribavirin in not recommended for dialysis patients, the addition of small doses of this compound to pegylated INF is discussed, especially for patients in whom previous infection treatment failed.
authors.affiliation: Department of Nephrology, Medical Faculty, Jagiellonian University, Krakow, Poland. wladsul@mp.pl
authors.forename: Władysław
authors.initials: W
authors.lastname: Sułowicz
authors.forename: Andrzej
authors.initials: A
authors.lastname: Radziszewski
authors.forename: Eve
authors.initials: E
authors.lastname: Chowaniec
mesh_terms: D000998:Antiviral Agents / Q000008:administration & dosage* / Q000009:adverse effects; D005060:Europe; D016679:Genome, Viral; D016174:Hepacivirus; D006526:Hepatitis C / Q000097:blood / Q000150:complications / Q000175:diagnosis / Q000188:drug therapy / Q000453:epidemiology / Q000635:transmission; D018937:Hepatitis C Antibodies / Q000097:blood; D006801:Humans; D016898:Interferon-alpha / Q000008:administration & dosage* / Q000009:adverse effects; D007564:Japan; D008103:Liver Cirrhosis / Q000097:blood / Q000188:drug therapy / Q000453:epidemiology / Q000209:etiology; D012367:RNA, Viral / Q000097:blood; D006435:Renal Dialysis; D012254:Ribavirin / Q000008:administration & dosage* / Q000009:adverse effects
chemical_list: D000998:Antiviral Agents; D018937:Hepatitis C Antibodies; D016898:Interferon-alpha; D012367:RNA, Viral; D012254:Ribavirin